Cleveland, OH – According to filings with the U.S. Securities and Exchange Commission, Convelo Therapeutics is raising $12,025,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Derrick Rossi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Convelo Therapeutics

Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimers. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.

To learn more about Convelo Therapeutics, visit http://convelotx.com/

Contact:
Derrick Rossi, Chief Executive Officer
216-658-3969

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved